[Features of course of pain syndrome in patients with schwannomatosis].
Elizaveta MakashovaA G VoloshinS V ZolotovaVladimir V StrelnikovAndrey V GolanovPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2024)
Further studies of the molecular features of schwannomatosis and driver mutations in the pathogenesis of pain are necessary to improve the effectiveness of pain therapy in this group of patients. Schwannomatosis is a disease from the group of neurofibromatosis, manifested by the development of multiple schwannomas. Neuropathic pain is one of the main symptoms characteristic of peripheral schwannomas, however, the severity and prevalence of the pain syndrome does not always correlate with the location of the tumors. According to modern concepts, the key factors influencing the characteristics of the pain syndrome are the target gene and the type of pathogenic variant. The most severe widespread pain is observed in patients with pathogenic variants in the LZRT1 gene, while patients with mosaic variants may not even have local pain associated with tumors. Patients with variants in SMARCB1 may have no pain or localized pain that responds well to surgical treatment.
Keyphrases
- neuropathic pain
- chronic pain
- pain management
- spinal cord
- copy number
- spinal cord injury
- stem cells
- systematic review
- ejection fraction
- gene expression
- end stage renal disease
- genome wide
- risk factors
- early onset
- peritoneal dialysis
- single molecule
- sleep quality
- replacement therapy
- patient reported outcomes
- patient reported